Malignant Pleural Mesothelioma: From the Bench to the Bedside

Plasma Cell Membrane Localization of c-MET Predicts Longer Survival in Patients with Malignant Mesothelioma: A Series of 157 Cases from the MESOPATH Group

(2012) Guénaëlle Levallet et al.   Journal of Thoracic Oncology

Biomarkers for Malignant Pleural Mesothelioma

(2012) Laurent Greillier et al.   Molecular Diagnosis & Therapy

Novel Intrapleural Therapies for Malignant Diseases

(2012) Andrew R. Haas et al.   RESPIRATION

Pleural Diseases in the Molecular Era – Time for More Answers: Introduction

(2012) Marios E. Froudarakis   RESPIRATION

Oncofetal Protein IMP3, a New Diagnostic Biomarker to Distinguish Malignant Mesothelioma From Reactive Mesothelial Proliferation

(2011) Min Shi et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Markers for the non-invasive diagnosis of mesothelioma: a systematic review

(2011) S van der Bij et al.   BRITISH JOURNAL OF CANCER

Advances in the biology of malignant pleural mesothelioma

(2011) P.A. Zucali et al.   CANCER TREATMENT REVIEWS

Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin

(2011) P. A. Zucali et al.   CLINICAL CANCER RESEARCH

Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors

(2011) G. I. Shapiro et al.   CLINICAL CANCER RESEARCH

Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509

(2011) Linda L. Garland et al.   Journal of Thoracic Oncology

Expert Opinions of the First Italian Consensus Conference on the Management of Malignant Pleural Mesothelioma

(2010) Carmine Pinto et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Consolidative Dendritic Cell-based Immunotherapy Elicits Cytotoxicity against Malignant Mesothelioma

(2010) Joost P. Hegmans et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics

(2010) Claire L. Mitchell et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

hsa-miR-29c* Is Linked to the Prognosis of Malignant Pleural Mesothelioma

(2010) H. I. Pass et al.   CANCER RESEARCH

Criteria for Scientific Evaluation of Novel Markers: A Perspective

(2010) K. G.M. Moons   CLINICAL CHEMISTRY

Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study

(2010) A. Scherpereel et al.   EUROPEAN RESPIRATORY JOURNAL

Phase II Study of Asparagine-Glycine-Arginine–Human Tumor Necrosis Factor α, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma

(2010) Vanesa Gregorc et al.   JOURNAL OF CLINICAL ONCOLOGY

Thymidylate Synthase But Not Excision Repair Cross-Complementation Group 1 Tumor Expression Predicts Outcome in Patients With Malignant Pleural Mesothelioma Treated With Pemetrexed-Based Chemotherapy

(2010) Luisella Righi et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma

(2010) Jenette Creaney et al.   Journal of Thoracic Oncology

Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma

(2010) Suresh S. Ramalingam et al.   Journal of Thoracic Oncology

Histone Deacetylase Inhibitors in Malignant Pleural Mesothelioma: Preclinical Rationale and Clinical Trials

(2010) Paul K. Paik et al.   Journal of Thoracic Oncology

A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307

(2010) Sarita Dubey et al.   Journal of Thoracic Oncology

Clinical Significance of Serum Vascular Endothelial Growth Factor in Malignant Pleural Mesothelioma

(2010) Akihiro Yasumitsu et al.   Journal of Thoracic Oncology

Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma

(2010) Rabab Gaafar et al.   LUNG CANCER

Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis and beyond

(2009) R D Riley et al.   BRITISH JOURNAL OF CANCER

Enhancing the apoptotic and therapeutic effects of HDAC inhibitors

(2009) Ailsa J. Frew et al.   CANCER LETTERS

Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines

(2009) Kiyonori Kai et al.   CANCER LETTERS

The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer

(2009) Scott A. Kono et al.   DRUG RESISTANCE UPDATES

Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

(2009) A. Scherpereel et al.   EUROPEAN RESPIRATORY JOURNAL

Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer

(2009) Ursula A. Matulonis et al.   JOURNAL OF CLINICAL ONCOLOGY

Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: A phase II prospective study

(2009) Tamara R. Tilleman et al.   JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma

(2009) Mor-Li Hartman et al.   JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines

(2009) Sara L. O’Kane et al.   LUNG CANCER

Inhibition of mesothelin–CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy

(2009) Raffit Hassan et al.   LUNG CANCER

Advantages of the nested case-control design in diagnostic research

(2008) Cornelis J Biesheuvel et al.   BMC Medical Research Methodology

Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma

(2008) David M. Jackman et al.   CANCER

Thymidylate Synthase Expression in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors

(2008) P. Ceppi et al.   CLINICAL CANCER RESEARCH

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

(2008) J. A. Engelman et al.   CLINICAL CANCER RESEARCH

PTEN expression is a strong predictor of survival in mesothelioma patients☆

(2008) Isabelle Opitz et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma

(2008) K. Okuda et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Clinical Efficacy and Predictive Molecular Markers of Neoadjuvant Gemcitabine and Pemetrexed in Resectable Non-small Cell Lung Cancer

(2008) Gerold Bepler et al.   Journal of Thoracic Oncology

Functional inactivation of NF2/merlin in human mesothelioma

(2008) Claudio Thurneysen et al.   LUNG CANCER

Pathophysiology of the Pleura

(2008) Michael A. Jantz et al.   RESPIRATION

Mechanisms of resistance to EGFR tyrosine kinase inhibitors: implications for patient selection and drug combination strategies

(2008) Alexandra Eyzaguirre et al.   Targeted Oncology

Mesothelin targeted cancer immunotherapy

(2007) Raffit Hassan et al.   EUROPEAN JOURNAL OF CANCER